恩瑞格需要注意的事项有什么呢？

(Deferasirox) chemical name is 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid. It is an iron chelator product developed by the Swiss pharmaceutical company Novartis. It is the first oral iron-removing agent approved by the US FDA for routine use. It is approved for use in patients ≥2 years old with chronic iron overload caused by blood transfusion. In Europe, it is recommended as a 6 As a first-line drug for patients with thalassemia and iron overload over the age of 18, Enrego is highly selective for iron (Fe3+). So what should patients pay attention to when using Enrige treatment?

1: Deferasirox, the main ingredient of Enriga, may cause rashes. Although the rash usually disappears automatically without the need to adjust the dosage or stop taking the medication, some patients may have more serious conditions or may continue to occur, so the medication must be stopped in time. Two: After taking this medicine, the patient's vision or hearing may be affected. Three: This medicine should be taken 30 minutes before meals. Four: The time of taking this medicine must be the same every day, so that the effect of the medicine will be better. Patients and friends should pay more attention to these precautions. 5: It is recommended that patients with iron accumulation, such as those who require long-term blood transfusion (blood transfusion volume up to 100 ml/kg) and whose serum ferritin exceeds 1000 μg/L, are initially recommended to take 20 mg/kg of deferasirox daily according to their body weight. Depending on the serum ferritin index, patients may need to adjust or increase the dose of deferasirox, which is usually 5 mg/kg or 10 mg/kg. The dose is adjusted in units of kilograms, but the total dose should not exceed 30 mg/kg per day.

VI: Gastrointestinal events: Gastrointestinal bleeding (including death) may occur; more common in patients with advanced hematological malignancies and/or elderly patients with low platelet counts; discontinue treatment for suspected gastrointestinal bleeding or ulceration. Nonfatal upper GI irritation, bleeding, and ulceration (sometimes complicated by GI perforation, including death) have been reported. Use concomitant medications with caution that may increase the risk of adverse gastrointestinal effects (eg, nonsteroidal anti-inflammatory drugs, corticosteroids, anticoagulants, oral bisphosphonates). Monitor patients closely for signs/symptoms of gastrointestinal ulceration/bleeding.